Tg Therapeutics (TGTX) Operating Expenses (2011 - 2026)

Tg Therapeutics' Operating Expenses history runs 16 years deep, the most recent figure standing at $170.1 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 51.58% year-over-year to $170.1 million in Q1 2026; TTM through Mar 2026 was $550.9 million, a 68.68% increase from a year earlier, with the FY2025 full-year figure at $493.0 million, up 71.72% from the prior year.
• Operating Expenses grew to $170.1 million in Q1 2026 per TGTX's latest filing, from $142.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $170.1 million in Q1 2026 and bottomed at $35.1 million in Q3 2022.
• The 5-year median for Operating Expenses is $71.4 million (2024), against an average of $81.4 million.
• Across the five-year window, Operating Expenses sank 59.78% in 2022 and jumped 85.24% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $77.6 million in 2022, then slipped by 27.27% to $56.5 million in 2023, then surged by 38.58% to $78.2 million in 2024, then jumped by 81.6% to $142.1 million in 2025, then grew by 19.74% to $170.1 million in 2026.
• Per Business Quant, the three latest TGTX Operating Expenses figures stand at $170.1 million (Q1 2026), $142.1 million (Q4 2025), and $132.3 million (Q3 2025).